Equity Research Analyst - Japan Team

We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand from enterprises to deploy ElevenAgents across sales, support, and operations. In 2022, we raised our first round at a $9 million valuation, which we announced alongside Eleven v1, our first Text to Speech model, and the first model to generate human-level speech. Four years later, as we reach our new valuation, we just released two new state-of-the-art Text to Speech models. Eleven v4 and v4 Turbo are our fastest and most emotive models yet, and are leading independent benchmarks. Alongside models, we have built a full interaction platform for AI. It allows organizations to deploy conversational agents, connected to their knowledge and systems, that interact naturally in any industry, geography, or context. This shift is driving much of our growth, with enterprise now accounting for 55% of our revenue, as businesses adopt ElevenAgents to support their customers and employees. Our technology is now used in daily operations at five of the world’s ten largest tech companies, five of the ten largest insurers, and four of the ten largest telecoms. The round was co-led by Wellington Management and T. Rowe Price, along with participation from Goldman Sachs, GIC, Ontario Teachers'​ Pension Plan, EQT Group, Sapphire Ventures, and BDT & MSD Partners. And grateful for ongoing support from existing investors including Andreessen Horowitz, Alkeon Capital, The D. E. Shaw Group, Disruptive, Evantic Capital, ICONIQ, and Lightspeed. Most of all, this round is for the team that built the last four years. We're just getting started! | 89 comments on LinkedIn

Immix Biopharma has priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, expecting gross proceeds of $125 million before deducting underwriting discounts and expenses. The offering is expected to close on or about 30 September 2026. The company intends to use the net proceeds to fund development of NXC-201, working capital, and general corporate purposes. NXC-201 is a CAR-T cell therapy being evaluated for relapsed/refractory AL Amyloidosis and has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the US FDA. J.P. Morgan is acting as sole book-running manager. The offering included participation from institutional investors including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments, and Wellington Management.

Temporal has raised $550 million in Series E funding at a $12.55 billion valuation, led by Lightspeed Venture Partners. Co-leads include Wellington Management, Growth Equity at Goldman Sachs Alternatives, and Tiger Global. The open-source platform, which powers AI applications, has seen significant growth in 2026. Its annualised revenue run rate recently surpassed $250 million, growing more than 200% year-over-year. Net dollar retention has exceeded 200% since February. Temporal Cloud processed 1.9 trillion actions in August, up more than 350% year-over-year. Open-source installs surpassed 43 million in August, up 134% since January 2026. The company now has more than 4,300 paying customers, including OpenAI, Snap, NVIDIA, Netflix, and JPMorgan Chase. Temporal provides infrastructure for reliable execution of critical applications, from payments to autonomous AI agents.